Search

The pathomechanism of alcoholic liver disease (ALD) involves cumulative events such as leaky gut, hepatocyte damage and inflammation that collectively contribute to the severity of disease. Our studies have delineated the role of Toll-like receptor 4 (TLR4) signaling and identified a unique role for...

microRNAs in Alcoholic Liver Disease Alcoholic liver disease affects millions of people worldwide and it remains to be a therapeutic challenge for clinicians. Activation of the inflammatory cascade via gut-derived lipopolysaccharide (LPS) contributes to alcoholic liver disease via induction of pro...

Neuroinflammation and Alzheimer’s disease The pathological role of interferon signaling is emerging in neuroinflammatory disorders, yet, the specific role of Interferon Regulatory Factor 3 (IRF3) in neuroinflammation remains poorly understood. Here, we show that global IRF3 deficiency delays TLR4...

Gyongyi Szabo, MD, PhD, FAASLD, AGAF, FACP Mitchell T. Rabkin, M.D. Chair Professor of Medicine and Faculty Dean for Academic Affairs Harvard Medical School Chief Academic Officer Beth Israel Lahey Health and Beth Israel Deaconess Medical Center Email: gszabo1@bidmc.harvard.edu Executive Assistant...

In our laboratory, we study mechanisms of innate immune activation in liver diseases and its role on modulation of liver parenchymal cells including hepatocytes and stellate cells. We employ a broad range of preclinical murine liver injury models of alcohol-associated hepatitis, metabolic...

Biomarkers in Liver Disease We are exploring novel therapies and biomarker discoveries in AH. Direct effects of alcohol on hepatocytes, increased intestinal permeability and activation of innate immune system (Kupffer cells) by gut-derived LPS are major factors in AH leading to over-activation of...